MetaVia Q2: $17.6mln cash, Phase 1 trial underway, AI-driven collaboration.

• MetaVia reports Q2 2025 financial results • Dosed first patient in Phase 1 trial for DA-1726 • Top-line data expected in Q4 2025 • Signed AI-driven collaboration with Syntekabio • $17.6M cash at end of Q2 2025 • Expected to fund company into 2026

MetaVia (NASDAQ:MTVA) has reported its Q2 2025 financial results, detailing a strategic AI-driven collaboration with Syntekabio and the extension of its Phase 1 trial for DA-1726. The company also announced a cash position of $17.6 million at the end of Q2 2025, which is expected to fund operations into 2026.

Financial Results

MetaVia reported net sales of $1.68 billion, a 1% decrease year-over-year (YoY), and net income of $65 million. The adjusted EBITDA stood at $280 million, with an adjusted earnings per share (EPS) of $0.24 [1]. The Laboratory Solutions segment showed sequential revenue growth, while the Bioscience Production segment saw a 3% increase in sales. Major contract extensions with leading pharmaceutical companies contributed to over $100 million in share gains [2].

AI Collaboration with Syntekabio

MetaVia has entered into a strategic research collaboration with Syntekabio to expand the therapeutic applications of its oral GPR119 agonist, DA-1241. The partnership will utilize Syntekabio's DeepMatcher® AI platform to screen DA-1241 against over 1,700 protein targets for new indications [3]. This collaboration follows positive Phase 2a results from a 16-week study involving 109 subjects, which demonstrated favorable safety and tolerability profiles, along with hepatoprotective and glucose-regulating effects in MASH patients. Initial insights from this AI-driven collaboration are expected later in 2025.

Phase 1 Trial Extension for DA-1726

MetaVia has extended the 48 mg multiple ascending dose (MAD) cohort of its Phase 1 trial for DA-1726 from 4 to 8 weeks. The company has successfully administered the fifth weekly dose to the first patient. The extension aims to evaluate longer-term early efficacy, safety, and explore the non-titrated maximum tolerated dose. Top-line data from the extended trial is expected in Q4 2025 [4].

Cash Position

At the end of Q2 2025, MetaVia reported $17.6 million in cash, which is expected to fund the company into 2026. This cash position supports the company's ongoing research and development efforts, including the AI collaboration with Syntekabio and the Phase 1 trial extension for DA-1726.

Conclusion

MetaVia's Q2 2025 financial results, AI-driven collaboration with Syntekabio, and Phase 1 trial extension for DA-1726 demonstrate the company's strategic focus on expanding the potential applications of its lead assets and maintaining a strong financial position. The company's ability to navigate near-term challenges and deliver long-term value to shareholders remains a key focus for management.

References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/AVTR/pressreleases/33845373/avantor-reports-q2-2025-financial-results/
[2] https://finance.yahoo.com/news/avantor-inc-avtr-q2-2025-070523356.html
[3] https://www.stocktitan.net/news/MTVA/meta-via-announces-ai-driven-collaboration-with-syntekabio-to-7f5r3gd9899p.html
[4] https://www.stocktitan.net/news/MTVA/meta-via-extends-48-mg-mad-portion-of-its-phase-1-clinical-trial-of-erfpp9lxv7cm.html